Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome
Kulcsszavak
Absztrakt
Leírás
Cornelia de Lange syndrome (CdLS) is a genetic condition caused by mutations in cohesin-related genes, mostly notably NIPBL. The CdLS phenotype includes physical features such as typical facies, limb abnormalities, short stature, and hirsutism as well developmental and behavioral manifestations such as intellectual disability, communication deficits, autistic traits and repetitive/self-injurious behaviors (RBs/SIB).
Behavioral challenges such as RBs/SIB pose a significant obstacle to quality of life to individuals with CdLS and families. In CdLS, disruption of developmental systems can impact neuronal and brain development, and impact GABAergic inhibitory interneuron formation, leading to RBs/SIB. Given the potential for dysregulated excitatory glutamatergic output in CdLS, neuronal oxidative stress may play a role in these maladaptive behaviors. NAC replenishes Central Nervous System (CNS) glutathione, a potent antioxidant and may ameliorate RBs/SIB. NAC has been shown to decrease maladaptive behaviors in autism and grooming disorders such as excoriation disorder (skin picking).
An 18-week cross-over trial is proposed to decrease RBs/SIB comprising two 8-week double-blinded active or placebo treatment with a 2-week wash out period in between. A cross-over design will afford for higher efficiency in sample size for similar power. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day. Participants will be recruited through CdLS Foundation.
Based on a mechanism for regulation glutamate transmission homeostasis in the central nervous system, the use of NAC may be particularly pertinent to individuals with CdLS. It is known that in CdLS genetic networks that impact on limb formation overlap significantly with developmental systems that impact neuronal and brain development, in particular GABAergic inhibitory interneuron formation. Given a dysregulated excitatory glutamatergic mechanism due to interneuron deficits, which can then lead to neuronal oxidative stress and programmed cell death, NAC may act as a key homeostatic regulator to prevent glutamate overactivity and neuronal damage in CdLS.
Dátumok
| Utolsó ellenőrzés: | 04/30/2020 |
| Első benyújtás: | 05/05/2020 |
| Becsült beiratkozás benyújtva: | 05/05/2020 |
| Első közzététel: | 05/10/2020 |
| Utolsó frissítés beküldve: | 05/11/2020 |
| Utolsó frissítés közzétéve: | 05/13/2020 |
| A tanulmány tényleges kezdési dátuma: | 07/31/2020 |
| Becsült elsődleges befejezési dátum: | 07/31/2021 |
| A tanulmány becsült befejezési dátuma: | 07/31/2021 |
Állapot vagy betegség
Beavatkozás / kezelés
Drug: N-acetyl cysteine
Other: Placebo
Fázis
Karcsoportok
| Kar | Beavatkozás / kezelés |
|---|---|
| Experimental: Group A: NAC 1800mg then Placebo NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks, followed by a 2-week wash-out period, followed by NAC Placebo-matching solution, orally every 8 hours, for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day. | |
| Experimental: Group B: Placebo then NAC 1800mg NAC Placebo-matching solution, orally every 8 hours, for 8 weeks, followed by a 2-week wash-out period, followed by NAC 1800 milligrams (mg), oral solution, every 8 hours for 8 weeks. Dosage will be titrated weekly starting at 600 mg daily and then increased by 600 mg every week to a target dose of 1800 mg per day. |
Jogosultsági kritériumok
| Tanulásra alkalmas korok | 13 Years Nak nek 13 Years |
| Tanulásra alkalmas nemek | All |
| Egészséges önkénteseket fogad | Igen |
| Kritériumok | Inclusion Criteria: - Ages 13 to 35 years - A diagnosis of CdLS as determined by a physician during routine care meeting the major and minor criteria from CdLS guidelines - Threshold criteria for the presence of RB/SIB as reported on initial screening Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders (CYBOCS-PDD) > 6 OR Aberrant Behavior Checklist (ABC) stereotypy subscale > 7) - Being able to attend 4 visits over the course of 18 weeks at the Johns Hopkins Hospital - No acute safety concerns or need for hospitalization due to psychotic, manic or depressive episode - Not currently pregnant or lactating/breastfeeding. Whether a participant is pregnant or not will be determined by the participant/caregiver report based on date last menses. If there is any suspicion of pregnancy, the PI will confer with the family to obtain testing through the primary care provider. Exclusion Criteria: - Allergy to NAC - Allergy to Quinine - Contraindication to NAC (organ transplant; untreated or symptomatic gastric condition) - Need for another medication with which NAC is contraindicated (antibiotics) |
Eredmény
Elsődleges eredménymérők
1. Change in Children's Yale-Brown Obsessive Compulsive Scale Modified for Pervasive Developmental Disorders (CYBOCS-PDD) repetitive behaviors measure score [Baseline, week 2, week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18]
2. Change in Aberrant Behavior Checklist (ABC) irritability self-injurious behaviors items score [Baseline, week 2, week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18]
Másodlagos eredménymérők
1. Change in Aberrant Behavior Checklist (ABC) irritability non-injurious behaviors items score [Baseline, week 2, week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18]
2. Change in total score of Parenting Stress Index/Short Form (PSI/SF) [Baseline, week 8, week 10, week 18]
3. Change in Burden Scale for Family Caregivers score [Baseline, week 8, week 10, week 18]
4. Change in Sensory Profile score [Baseline, week 8, week 10, week 18]
5. Change in Childhood Autism Rating Scale (CARS2) score [Baseline, week 8, week 10, week 18]
6. Change in Vineland adaptive Behavior Scale (VABS) score [Baseline, week 8, week 10, week 18]
7. Change in Clinical Global Impression - Severity of Illness (CGI-S) score [Baseline, week 8, week 10, week 18]
8. Change in Side Effects Survey [Baseline, week 2, week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18]
